PLX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

16.80M

-7.76%

0.055

+83.33%

18.70M

+84.91%

0.035

-61.11%

19.50M

+24.54%

0.040

-180%

Estimates Revision

The market is revising Upward the revenue expectations for Protalix BioTherapeutics, Inc. (PLX) for FY2025, with the revenue forecasts being adjusted by 2.62% over the past three months. During the same period, the stock price has changed by -8.38%.

Revenue Estimates for FY2025

Revise Upward

+2.62%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+25%

In Past 3 Month

Stock Price

Go Down

-8.38%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Protalix Biotherapeutics Inc (PLX.A) is 10.23, compared to its 5-year average forward P/E of 4.69. For a more detailed relative valuation and DCF analysis to assess Protalix Biotherapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

4.69

Current PE

10.23

Overvalued PE

20.06

Undervalued PE

-10.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.30

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.01

Undervalued EV/EBITDA

-0.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.95

Current PS

1.92

Overvalued PS

3.07

Undervalued PS

0.83

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PLX News & Events

Events Timeline

No data

News

4.0

11-21Benzinga

HC Wainwright & Co. Reaffirms Buy Rating for Protalix BioTherapeutics, Adjusts Price Target to $12

9.0

11-03Globenewswire

Chiesi Global Rare Diseases and Protalix BioTherapeutics Request EMA Re-evaluation of Negative Opinion on Elfabrio (pegunigalsidase alfa) Four-Week Dosing Regimen in the EU

7.0

10-28PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX

People Also Watch

Frequently Asked Questions

What is Protalix Biotherapeutics Inc (PLX) stock price today?

The current price of PLX is 1.75 USD — it has decreased -2.23 % in the last trading day.

What is Protalix Biotherapeutics Inc (PLX)'s business?

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

What is the price predicton of PLX Stock?

Wall Street analysts forecast PLX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Protalix Biotherapeutics Inc (PLX)'s revenue for the last quarter?

Protalix Biotherapeutics Inc revenue for the last quarter amounts to 17.85M USD, decreased -0.60 % YoY.

What is Protalix Biotherapeutics Inc (PLX)'s earnings per share (EPS) for the last quarter?

Protalix Biotherapeutics Inc. EPS for the last quarter amounts to 0.03 USD, decreased -25.00 % YoY.

What changes have occurred in the market's expectations for Protalix Biotherapeutics Inc (PLX)'s fundamentals?

How many employees does Protalix Biotherapeutics Inc (PLX). have?

Protalix Biotherapeutics Inc (PLX) has 207 emplpoyees as of December 15 2025.

What is Protalix Biotherapeutics Inc (PLX) market cap?

Today PLX has the market capitalization of 143.95M USD.